# EDGAR Filing Document

**Accession Number:** 0001113423
**File Stem:** 0001493152-26-022002
**Filing Date:** 2026-5
**Character Count:** 8342
**Document Hash:** e09a28fd4b3a67e94a22eff16c35c0ae
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-26-022002.hdr.sgml**: 20260508

**ACCESSION NUMBER**: 0001493152-26-022002

**CONFORMED SUBMISSION TYPE**: SC 13E3/A

**PUBLIC DOCUMENT COUNT**: 3

**FILED AS OF DATE**: 20260508

**DATE AS OF CHANGE**: 20260508

**SUBJECT COMPANY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COSCIENS Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001113423
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13E3/A
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 005-51184
- **FILM NUMBER:** 26959254

**BUSINESS ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7
- **BUSINESS PHONE:** 843-900-3201

**MAIL ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aeterna Zentaris Inc.
- **DATE OF NAME CHANGE:** 20040617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AETERNA LABORATORIES INC
- **DATE OF NAME CHANGE:** 20000503
**FILED BY**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** COSCIENS Biopharma Inc.
- **CENTRAL INDEX KEY:** 0001113423
- **STANDARD INDUSTRIAL CLASSIFICATION:** PERFUMES, COSMETICS & OTHER TOILET PREPARATIONS [2844]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 000000000
- **STATE OF INCORPORATION:** A6
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** SC 13E3/A

**BUSINESS ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7
- **BUSINESS PHONE:** 843-900-3201

**MAIL ADDRESS:**
- **STREET 1:** C/O NORTON ROSE FULBRIGHT CANADA LLP
- **STREET 2:** 222 BAY STREET, SUITE 3000, PO BOX 53
- **CITY:** TORONTO
- **STATE:** A6
- **ZIP:** M5K 1E7

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Aeterna Zentaris Inc.
- **DATE OF NAME CHANGE:** 20040617

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AETERNA LABORATORIES INC
- **DATE OF NAME CHANGE:** 20000503

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**Amendment No. 2 to** 

**SCHEDULE 13E-3**

**Rule 13e-3 Transaction Statement<br> (Pursuant to Section 13(e) of the Securities Exchange Act of 1934)**

**COSCIENS Biopharma Inc.**

(Name of the Issuer)

**COSCIENS Biopharma Inc.**<br> (Name of Persons Filing Statement)

**Common Stock, No Par Value per Share**

(Title of Class of Securities)

**22112H101**

(CUSIP Number of Class of Securities)

---

| | |
|:---|:---|
| **Peter Puccetti** |  |
| **Interim CEO and Chairman of the Board** |  |
| COSCIENS Biopharma Inc. | **Scott Saks** |
| **Telephone: (843) 900-3223** | **Norton Rose Fulbright US LLP** |
| **E-mail:** | **1301 Avenue of the Americas** |
| **c/o Borden Ladner Gervais, LLP,** | **New York, New York 10019-6022** |
| **22 Adelaide Street West, Suite 3400,** | **United States** |
| **Toronto ON M5H 4E3, Canada** | **(212) 318-3151** |

---

(Name, Address, and Telephone Number of Person Authorized to Receive Notices and Communication on<br> Behalf of Person(s) Filing Statement)

This statement is filed in connection with (check the appropriate box):

a. ☒ The
 filing of solicitation materials or an information statement Notice subject to Regulation 14A, Regulation 14C or Rule 13e-3(c) under
 the Securities Exchange Act of 1934.

b. ☐ The
 filing of a registration statement under the Securities Act of 1933.

c. ☐ A
 tender offer.

d. ☐ None
 of the above.

Check the following box if the soliciting materials or information statement referred to in checking box (a) are preliminary copies: ☒

Check the following box if the filing is a final amendment reporting the results of the transaction: ☐

**Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of this transaction, passed upon the merits or fairness of this transaction, or passed upon the adequacy or accuracy of the disclosure in this transaction statement on Schedule 13E-3. Any representation to the contrary is a criminal offense.**

**INTRODUCTION**

This Amendment No. 2 to Rule 13e-3 Transaction Statement on Schedule 13E-3 (the "**Transaction Statement**") is being filed by COSCIENS Biopharma Inc. (referred to herein as "**Company**" or "**subject company**" or "**filing person**") with the Securities and Exchange Commission (the "**Commission**").

This Amendment No. 2 to the Transaction Statement is being filed with the Commission solely to amend Item 16 of the Schedule 13E-3 to add as exhibit (a)(2)(v) the Notice of Annual General and Special Meeting of Shareholders of the Company (the "Notice of Meeting") which is being filed concurrently with a Report on Form 6-K furnished by the Company to the Commission.

Except as set forth in this Amendment No. 2 to the Transaction Statement, all information in the Transaction Statement remains unchanged.

**Item 16. Exhibits.**

---

| | |
|:---|:---|
| a(2)(i) | [Draft Notice of Annual and Special Meeting of Shareholders and Management Proxy Circular, including all appendices thereto, as amended.\*](https://www.sec.gov/Archives/edgar/data/1113423/000149315226020983/exa2-i.htm) |
| (a)(2)(ii) | [Preliminary Form of Proxy.\*](https://www.sec.gov/Archives/edgar/data/1113423/000149315226020983/exa2-ii.htm) |
| (a)(2)(iii) | [Preliminary Letter of Transmittal.\*](https://www.sec.gov/Archives/edgar/data/1113423/000149315226020983/exa2-iii.htm) |
| (a)(2)(iv) | [Press Release issued by the Company, dated April 20, 2026, incorporated herein by reference to Exhibit 99.2 to the Report on Form 6-K furnished by the Company to the Commission on April 20, 2026.\*](https://www.sec.gov/Archives/edgar/data/1113423/000149315226020983/exa2-iv.htm) |
| (a)(2)(v) | [Notice of Annual General and Special Meeting of Shareholders of the Company.](exa2-v.htm) |
| (b) | Not applicable. |
| (c) | [Fairness Opinion of Segal dated as of April 16, 2026.\*](https://www.sec.gov/Archives/edgar/data/1113423/000149315226020983/exc.htm) |
| (d) | Not applicable. |
| (f) | Not applicable. |
| (g) | Not applicable. |
| 107 | [Filing Fee Table.\*](https://www.sec.gov/Archives/edgar/data/1113423/000149315226018001/ex107.htm) |

---

\* Previously filed.

**SIGNATURES**

After due inquiry and to the best of my knowledge and belief, I certify that the information set forth in this Transaction Statement is true, complete, and correct.

---

| | |
|:---|:---|
| COSCIENS BIOPHARMA INC. | COSCIENS BIOPHARMA INC. |
| By: | */s/ Giuliano La Fratta* |
| Name: | Giuliano La Fratta |
| Title: | Chief Financial Officer |

---

Dated: May 8, 2026

## Ex-99.(A)(2)(V)

**Exhibit (a)(2)(v)**

---

| | |
|:---|:---|
| May 8, 2026 | ![](exa2-v_001.jpg)<br> 650 De Maisonneuve Blvd., 7th Floor<br> Montreal QC, H3A 3T2<br> <u>www.computershare.com</u> |

---

To: All Canadian Securities Regulatory Authorities

**Subject: COSCIENS Biopharma Inc.**

Dear Sir/Madam:

We advise of the following with respect to the upcoming Meeting of Security Holders for the subject Issuer:

---

| | |
|:---|:---|
| Meeting Type : | Annual General and Special Meeting |
| Record Date for Notice of Meeting : | May 18, 2026 |
| Record Date for Voting (if applicable) : | May 18, 2026 |
| Beneficial Ownership Determination Date : | May 18, 2026 |
| Meeting Date : | **June 17, 2026** |
| Meeting Location (if available) : | **Virtual Meeting** |
| Issuer sending proxy related materials directly to NOBO: | No |
| Issuer paying for delivery to OBO: | Yes |

---

---

| | |
|:---|:---|
| **Notice and Access (NAA) Requirements:** |  |
| NAA for Beneficial Holders | No |
| NAA for Registered Holders | No |

---

**Voting Security Details:**

---

| | | |
|:---|:---|:---|
| **Description** | **CUSIP Number** | **ISIN** |
| COMMON SHARES | 22112H101 | CA22112H1010 |

---

Sincerely,

**Computershare**

Agent for COSCIENS Biopharma Inc.